Physician profile
Barbara Denysiak
NPI 1003085572
$17,626.45
in general payments reported to CMS, 2019-2025
32 companies · $2,316 in 2025
The $2,316 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,423 · 2020: $581 · 2021: $2,210 · 2022: $5,631 · 2023: $2,860 · 2024: $2,606 · 2025: $2,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,781.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,313.38 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals LP | $2,417.65 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $2,383.00 | 2019-2025 | Xarelto, Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $2,366.26 | 2022 | |
| Gilead Sciences, INC. | $1,593.28 | 2021-2025 | Descovy, Yeztugo |
| Glaxosmithkline, LLC. | $1,273.50 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $756.68 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Vanda Pharmaceuticals INC. | $710.37 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $637.68 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $590.69 | 2022-2025 | |
| Lilly USA, LLC | $332.33 | 2019-2025 | Mounjaro, Zepbound |
| Viiv Healthcare Company | $232.65 | 2023-2025 | Apretude |
| Si-Bone, INC. | $219.93 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $145.41 | 2019-2021 | |
| Pfizer INC. | $111.17 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.18 | 2020-2024 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $68.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $51.41 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.38 | 2023 | Xifaxan |
| Ibsa Pharma INC. | $35.43 | 2023 | Tirosint, Licart |
| Astellas Pharma US INC | $34.25 | 2025 | Veozah |
| Terumo Bct, INC. | $29.76 | 2022 | |
| Radius Health, INC. | $29.42 | 2023 | |
| Corcept Therapeutics | $23.79 | 2025 | Korlym |
| Exact Sciences Corporation | $23.06 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $20.21 | 2025 | Repatha |
| Philips North America LLC | $19.76 | 2024 | (Ck7) Extended Holter |
| Baxter Healthcare | $19.71 | 2024 | Hillrom - Eli280 Cardiograph |
| Mannkind Corporation | $19.33 | 2025 | |
| Abbott Laboratories | $18.36 | 2023 | Octrode |
| Boston Scientific Corporation | $17.24 | 2020 | |
| Spinal Simplicity, LLC | $15.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Denysiak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.